 Vyant Bio NASDAQ:VYNT Inc revealed that it is advancing its repurposed drug candidate, VYNT-0126 to treat Rett Syndrome, into clinical trials early next year based on pre-clinical efficacy data and following encouragement and guidance from the International Rett Syndrome Foundation IRSF, the company said as it posted second-quarter results. With our preclinical data with VYNT-0126, which we believe is compelling, we met with the Clinical Trial Committee of the International Rett Syndrome Foundation on July 19, 2022, to receive their feedback and guidance on our plans to conduct a proof-of-concept clinical trial of VYNT-0126 in adult Rett patients in Australia, Vyant chief scientific officer Robert Fremeau said in a statement accompanying the results. 